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Vaccination alone is not sufﬁciently effective to protect human from post-exposure rabies virus infection
due to delayed generation of rabies virus neutralizing antibodies and weak cellular immunity. Therefore,
it is vital to develop safer and more efﬁcacious vaccine against rabies. PIKA, a stabilized chemical analog
of double-stranded RNA that interacts with TLR3, was employed as adjuvant of rabies vaccine. The
efﬁcacy and safety of PIKA rabies vaccine were evaluated. The results showed that PIKA rabies vaccine
enhanced both humoral and cellular immunity. After viral challenge, PIKA rabies vaccine protected 70–
80% of animals, while the survival rate of non-adjuvant vaccine group (control) was 20–30%. According to
the results of toxicity tests, PIKA and PIKA rabies vaccine are shown to be well tolerated in mice. Thus,
this study indicates that PIKA rabies vaccine is an effective and safe vaccine which has the potential to
develop next-generation rabies vaccine and encourage the start of clinical studies.
& 2016 Published by Elsevier Inc.Introduction
Rabies is a zoonosis that is transmitted from animal to human
through contamination of a bite or scratch with saliva-borne virus,
or through intact mucous membrane (Manning et al., 2008). The
mortality rate is almost 100% after the onset of the clinical
symptoms and it remains one of the most lethal infectious dis-
eases known (Rupprecht et al., 2002).
Current strategy to prevent rabies infection recommended by
WHO includes post-exposure vaccination and inoculation of anti-
rabies immunoglobulins (preferably human rabies immunoglo-
bulin, HRIG) around the wound site for severe injury (World
Health Organization, 2013). However, there are more than 55,000
deaths cause by rabies infection every year (Huang et al., 2015). A
study evolving 725 human rabies cases in China, Guangxi pro-
vince, showed that 197 death cases were caused by vaccination
failure; amongst which 78.27% cases died before the 4th injection
was administered (Wang, 2010). It is indicated that vaccination
alone cannot effectively protect human from rabies virus infection.
Rabies virus replicated rapidly and is capable of paralyzing theu),
m (L. Li).host central nervous system in days. If the victim suffered from
severe multiple bites from an infected animal, the incubation
period can be less than one week. Once signs of disease begin, the
mortality rate is almost 100%. Therefore, vaccines must generate
immediate and appropriate immune responses so that rabies virus
could be eliminated before entering the nervous system. To
eliminate the rabies virus, two requirements are needed, i.e., the
production of rabies virus neutralizing antibodies (RVNA) for
neutralizing the biological effects of rabies virus and the induction
of cellular immunity for removing virus-infected cells (Huang et
al., 2015; Jayakumar and Ramadass, 1990; Thraenhart et al., 1994).
However, available vaccines failed to achieve this. Therefore, a
more reliable and cost effective post-exposure vaccine which
could induce earlier and higher titer of RVNA and strong cellular
immunity is in need.
A novel adjuvant, PIKA, is introduced to the rabies vaccine in
our study. The PIKA is a stabilized chemical analog of double-
strand RNA capable of inducing non-speciﬁc immunity. Our pre-
vious studies showed that PIKA adjuvant acts through toll-like
receptor 3 (TLR-3) and other cellular pathways, enhancing antigen
presentation by antigen-presenting cells (APCs) and inducing
production of pro-inﬂammatory cytokines (Lau et al., 2009, 2010).
According to the standard of Guideline on the Requirements for
Quality Documentation Concerning Biological Investigational Medic-
inal Products and Chinese Requirements for Biological Products
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vaccine (PIKA-RV). The PIKA rabies vaccine was tested in mice for
efﬁcacy of humoral immunity, cellular immunity and the protec-
tion after wild viral challenge. In addition, we developed an
accelerated regimen which could be completed in 7 days post
exposure. Safety of PIKA and PIKA-RV after single and repeated
dose administration was also established.Results
Evaluation of rabies-speciﬁc antibody response in vaccinated mice
To assess the immune response of PIKA-RV, rabies virus neu-
tralization response in PIKA-RV-immunized mice was measured after
21 days of the ﬁrst immunization. As shown in Fig. 1, high con-
centration PIKA-RV group (0.2 IU IPRVþ100 μg PIKA) produced
almost 3-fold higher RVNA titer compared to IPRV alone (47.41 versus
16.01 IU/mL, respectively; Po0.001). There was also a signiﬁcant
increase in RVNA titer in the group receiving median concentration
PIKA-RV (0.02 IU IPRVþ10 μg PIKA) (Po0.01). More interestingly,
low concentration PIKA-RV (0.002 IU IPRVþ1 μg PIKA) also produced
a slightly higher RVNA response.
Cell mediated immune response in vaccinated mice
Another critical feature of vaccines is the ability to induce
cellular immunity, most effective in removing virus-infected cells
(La Gruta and Turner, 2014; Visperas et al., 2014; Welten et al.,
2013). To determine whether T cells were activated, the fre-
quencies of IFN-γ-producing cells at the single-cell level by ELI-
SPOT assay were determined following stimulation of mouse
spleen lymphocytes with IPRV.
Splenocytes of high concentration PIKA-RV group (0.2 IU
IPRVþ100 μg PIKA) generated approximately 73 SFU/3105 of
IFN-γ speciﬁc splenocytes, which was signiﬁcantly higher than the
group treated with IPRV (Po0.01, Fig. 2). Similarly, the number of
IFN-γ-secreting cells generated in mice primed with median
concentration PIKA-RV group (0.02 IU IPRVþ10 μg PIKA) was also
higher than that in mice primed with IPRV (Po0.001).Fig. 1. PIKA enhanced antigen-speciﬁc antibody production. Mice (n¼6) were
immunized by i.m. injection of 100 μL PIKA-RV with different concentrations, IPRV,
or PBS control. The preparations were injected on day 0 and 7. Blood was collected
at day 21 after the ﬁrst immunization. Rabies virus neutralizing antibody titer were
evaluated using the FAVN test. Data are expressed as the mean7SEM (n¼6;
*Po0.05; ***Po0.001).Protection of immunized animals against rabies virus challenge
To test whether PIKA-RV can elicit enough protective immunity
against a robust rabies virus challenge in animal model, two
challenge tests were performed.
In the ﬁrst challenge test, Beagles and wild virus BD06 strain
were employed. All Beagles were challenged with BD06 strain and
immunized with different experimental materials post exposure.
Their survival was monitored for 45 days. By day 9, animals began
to develop clinic signs. Beagles died within 1–3 days after the
onset of abnormal symptoms. Densely distributed ﬂorescent spots
were observed after direct immunoﬂuorescence staining of rabies
virus in brain tissue, indicating death caused by rabies viral
infection in CNS. Group of vaccine control only confer limited
protection (30%), while PIKA-RV protected 70% of the animals as
shown in Fig. 3.
In another challenge test, wild virus BD06 strain was prepared
for infection at 50LD50. Golden hamsters in all testing group
behaved normal 5 days after infection. Infected hamsters that did
not survive started to show clinical symptoms, such as decreased
activities, clumsiness, poor coordination, decreased food intake
and anxiety, between day 6 and 14. Hamsters died within 4–6 days
after the onset of abnormal symptoms. Densely distributed ﬂor-
escent spots were also observed, indicating death caused by rabies
viral infection in CNS. The survival rate for all testing groups was
demonstrated in Fig. 4. 80% of hamsters died in vaccine controlFig. 2. Robust T-cell responses were generated upon re-stimulation with IPRV
in vitro. Splenocytes from the immunized mice were isolated 21 days after the ﬁrst
immunization and were re-stimulated with IPRV in vitro for 20 h. The ﬁgure shows
the number of IFN-γ secreting cells as determined by ELISPOT assay. Data are
expressed as the mean7SEM (n¼6; *Po0.05, ***Po0.001).
Fig. 3. Post-exposure test in Beagles. Animal (Golden Hamster) survival rates (%)
after wild strain virus challenge followed by immunization with (1) PBS, (2) vaccine
control and (3) PIKA-RV post exposure.
Fig. 4. Regimen study. Animal (Golden Hamster) survival rates (%) after wild rabies virus challenge followed by immunization with (1) saline solution by standard schedule,
(2) vaccine control by standard schedule, (3) human rabies immunoglobulin (HRIG, 0.75IU administered at each site of right and left hind leg 2 h post exposure), (4) PIKA-RV
by standard schedule), or (5) PIKA-RV by accelerated schedule post exposure.
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niﬁcantly higher protection using the standard regimen.
To further improve the protective activity and elevate patient
compliance, we developed an accelerated regimen. Then we make
a comparison between the accelerated regimen and the standard
regimen. As shown in Fig. 4, the PIKA-RV administered using the
accelerated regimen protected 80% of the mice, similar to that of
passive immunization with HRIG. Compared with the standard
regimen, the accelerated regimen enhanced the survival rate from
67.7% to 80%.
Acute toxicity test
Animals in PIKA and PIKA-RV groups did not show signiﬁcant
variations in food intake and body weight compared to the control
group. No mortality was observed in any groups. All animals did
not show observable toxic reactions and abnormalities during
organ visual examination. The maximum dosage of PIKA adjuvant
and PIKA-RV up to 10 mL/kg by body weight was well tolerated by
test animals, which was equivalent to 300 times of human dosage.
Repeated dose toxicity
The ICH guideline on the Preclinical Safety Evaluation of
Biotechnology-Derived Pharmaceuticals (“ICH S6”) states that “the
frequency of administration in laboratory animals may be increased
compared to the proposed schedule for the human clinical studies
in order to compensate for faster clearance rates or low solubility of
the active ingredient”. Therefore, in repeated dose toxicity study,
our treatment schedule in mice was double dose administration on
day 0 and day 2, and single dose administration on days 7, 28 and
42. This treatment schedule could be employed to study the repe-
ated dose toxicity of the accelerated postexposure regimen and the
four-dose regimen. For the accelerated postexposure regimen, the
treatment schedule increased the frequency of vaccination on days
28 and 42. For the four-dose regimen, the treatment schedule
increased the frequency of vaccination on day 42. The dosage of
high dose of PIKA-RV group was equivalent to 242 times of human
dosage.
There were no treatment-related differences in mean body
weights and food consumption of males or females from any
treatment group compared to control group.
Hematology
Blood samples from both genders were collected on day 44 and
56 for hematology analysis. Results of the 44th day for male and
female mice in all testing groups including PIKA adjuvant and
PIKA-RV groups are tabulated in Table 1a and b respectively. Onday 44, male mice in PIKA-RV high dose group had lower level of
LY and higher level of GR (Po0.01), whilst female mice in PIKA-RV
high dose group had lower level of HGB (Po0.01) and HCT
(Po0.05). However, there was no signiﬁcant difference in PIKA
group and PIKA-RV low dose group. On day 56, these difference
had disappeared. No pathological association was established as
the changes are within the normal reference range for mice.
Biochemistry
Blood samples were collected on the same day as the hema-
tology test, they were used for blood biochemistry and electrolytes
analysis. Male mice in PIKA adjuvant group showed increasing AST
and CK value after ﬁnal vaccination dose, while female mice
showed a decrease level of ALP (Po0.05). For PIKA-RV low dose
group, decreasing total bilirubin was observed among male mice
and decreasing ALP was observed among female mice (Po0.01).
Similarly for the high dose group, female mice had increasing ALP
level compare to baseline (Po0.01).
The electrolytes for all animals in all testing groups did not show
any signiﬁcant ﬂuctuation during the testing period. Though the
above mentioned shifts in value of biochemistry parameters were
statistically signiﬁcant, they were still within the normal reference
ranges for the species. The value for all biochemistry parameters and
electrolytes are listed in Table 2a and b respectively.
Organ/body weight ratios
Mice in all study groups were sacriﬁced by the end of study
period with organ weighted, dissected and examined for patho-
logical changes. Spleen of male mice in PIKA-RV high dose group
increased signiﬁcantly compared to saline control (Po0.05). The
weight of female mice spleen also increased for PIKA adjuvant
group. The changes in the weights reﬂected the increasing
immune response induced by vaccination and adjuvant activity.
The weight changes for other organ were found to be statistically
non-signiﬁcant in all treated groups, thus had no pathological
signiﬁcance. Organ weights for both male and female mice in all
study groups are presented in Table 3a and b.
Histopathology
The systemic pathological analysis found no treatment-related
lethal changes. After the ﬁnal vaccination, inguinal lymph nodes
around injection site and spleen showed different degree of
hyperplasia for mice in all study groups. The hyperplasia of lymph
nodes and spleen was dosed-dependent. By the end of study
period, hyperplasia of the organ returned to normal.
Table 1
Hematology parameter changes of the 44th day for male and female mice treated with different test materials.
WBC RBC HGB HCT MCV MCH MCHC PLT RDW PCT MPV PDW Ret LY MO GR
(109/L) (1012/L) (g/L) (%) (fL) (Pg) (g/L) (109/L) (%) (%) (fL) (%) (‰) (%) (%) (%)
a. Male mice hematology parameters for 4 study groups
Saline 2.571.3 8.0671.59 125725 39.277.8 48.773.2 15.470.9 317713 4657144 13.471.1 0.2170.07 4.670.3 14.170.3 1776 71.777.6 11.172.5 17.277.2
PIKA 2.571.0 8.5270.41 13378 40.272.8 47.373.5 15.670.7 331722 549754 13.270.4 0.2670.03 4.770.2 13.770.3 1776 65.977.9 15.173.7 19.076.0
PIKA-RV (low dose) 2.971.0 7.6972.59 132711 40.273.1 46.472.8 15.270.6 328713 5807125 12.470.3 0.2670.07 4.670.2 13.670.4 1776 68.774.3 14.374.4 17.077.7
PIKA-RV (high dose) 3.171.7 8.7370.48 13278 41.372.7 47.573.6 15.270.9 321721 5967158 13.971.5 0.2870.08 4.870.2 13.570.6 1775 59.4710.0** 11.973.2 28.7710.3**
b. Female mice hematology parameters for 4 study groups
Saline 3.371.3 7.5273.77 158711 48.671.9 51.273.4 16.670.5 326718 577767 13.070.5 0.2670.03 4.770.2 13.970.4 673 68.179.0 12.972.9 19.077.8
PIKA 3.972.0 7.8472.75 142714 45.273.4 51.374.4 16.070.8 314720 536794 12.870.4 0.2670.05 4.970.2 13.870.4 574 62.278.3 14.174.2 23.778.0
PIKA-RV (low dose) 3.771.5 8.1372.71 146714 44.876.4 48.974.2 16.070.7 328719 595784 13.371.0 0.2870.04 4.770.2 13.570.5 573 62.1711.8 12.273.9 25.779.3
PIKA-RV (high dose) 2.870.6 8.7370.77 139710* 41.473.2** 47.672.3 15.970.9 33576 5317109 12.870.5 0.2670.06 4.970.4 13.970.4 673 61.4712.2 13.372.8 25.3713.7
Values are expressed as mean7standard deviation.
WBC – White Blood Cells, RBC – Red Blood Cells, HGB – Hemoglobin, HCT – Hematocrit, MCV – Mean Corpuscular Volume, MCH – Mean Corpuscular Hemoglobin, MCHC – Mean Corpuscular Hemoglobin Concentration, PLT –
Platelets, RDW – Red Cell Distribution Width, PCT – Plateletcrit, MPV – Mean Platelet Volume, PDW – Platelet Distribution Width, Ret – Reticulocyte, LY – Lymphocyte, MO – Monocyte number, GR – Granulocyte.
nn indicates signiﬁcant increase or decrease in value with p.
Table 2
Clinical chemistry parameter changes of the 44th day for male and female mice treated with different test materials.
ALT AST TP Alb T.BiLi Urea Cre Glu CK ALP CHO TG Naþ Kþ Cl
(U/L) (U/L) (g/L) (g/L) (μmol/L) (mmol/L) (μmol/L) (mmol/L) (U/L) (U/L) (mmol/L) (mmol/L) (mmol/L) (mmol/L) (mmol/L)
a. Male mice biochemistry parameters for 4 study groups
Saline 3179 84723 46.779.4 15.575.5 1.471.0 9.3773.89 5.5714.0 6.4674.38 60740 26.5724.8 1.4571.50 0.3770.52 150.374.4 6.8971.67 119.172.8
PIKA 47723 142792* 49.676.9 16.871.2 1.470.4 9.1471.99 17.072.8 9.5273.58 204763* 47.5725.5 3.2571.64 0.6870.55 150.776.5 6.3570.60 118.275.8
PIKA-RV (low dose) 41720 75764 56.6711.1 10.978.5 0.170.9** 5.5274.55 2.9727.2 10.36710.54 1047165 20.6722.5 2.4272.60 0.3270.56 149.974.6 7.0071.66 118.275.2
PIKA-RV (high dose) 3576 112734 46.2718.2 14.975.7 0.871.0 7.3273.03 9.9716.3 9.6875.67 94787 38.1716.7 3.3271.57 0.5670.26 152.375.7 6.5370.56 121.575.9
b. Female mice biochemistry parameters for 4 study groups
Saline 2475 82713 52.973.6 19.871.2 0.670.2 8.4471.73 25.3720.7 11.1871.33 54715 81.7718.5 3.0070.25 0.8470.43 162.372.6 6.6970.87 129.272.2
PIKA 2474 7678 51.474.4 18.471.4 0.270.2 7.7371.90 12.3712.2 9.4573.60 39724 54.4731.1* 2.4970.94 0.6470.30 163.072.9 6.3470.22 128.872.8
PIKA-RV (low dose) 2374 7878 52.373.3 17.670.7 0.170.2 8.7674.48 22.275.8 12.9172.34 46711 54.3723.8* 2.4670.60 0.5570.28 163.872.8 6.7670.40 130.172.7
PIKA-RV (high dose) 2374 8179 53.573.1 18.171.4 0.170.4 8.0071.86 18.373.3 11.9171.48 51716 54.0718.9* 3.0970.36 0.8370.66 163.871.6 6.8270.92 129.770.3
Values are expressed as mean7standard deviation.
ALT – Alanine transaminase (formly called glutamic-pyruvic transaminase), AST – Aspartate transaminase, TP – total protein, Alb – albumin, T.BiLi – total bilirubin, Urea – Urea, Cre – creatinine, Glu – glucose, CK – creatine kinase,
ALP – alkaline phosphatase, CHO – cholesterol, TG – triglyceride.
n indicates signiﬁcant increase or decrease in value with p.
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Table 3
Organ/body weight ratios (mg/10 g body weight) of the 56th day for male and female mice treated with different test materials.
a. Male mice organ/body weight ratios for 4 study groups
Heart Liver Spleen Lung Brain Thyroid Kidney Testes Epididymis
Saline 50.476.0 466.1752.5 32.874.5 69.1712.6 142.579.0 12.573.8 179.8724.6 73.179.2 27.172.9
PIKA 54.077.4 436.2727.2 35.574.6 63.075.5 140.7718.6 10.773.6 171.7718.5 75.7712.7 29.775.0
PIKA-RV (low dose) 51.175.4 457.9750.5 40.175.3 59.878.1 140.279.6 12.474.6 172.7711.9 70.477.9 30.473.8
PIKA-RV (high dose) 53.475.9 475.7738.2 41.0710.3* 74.1712.5 145.976.9 11.872.9 193.4729.7 79.0712.1 28.177.0
b. Female mice organ/body weight ratios for 4 study groups
Heart Liver Spleen Lung Brain Thyroid Kidney Uterus Ovary
Saline 51.374.8 495.6733.1 40.475.0 73.2715.0 177.4717.6 16.376.7 142.279.3 55.8723.0 8.471.4
PIKA 51.374.2 500.7744.5 55.6715.8** 78.6718.7 182.777.2 20.574.5 142.277.1 60.3726.2 8.972.9
PIKA-RV (low dose) 54.674.5 486.2720.5 49.377.6 81.1713.2 186.6713.9 18.174.4 147.4710.4 67.6738.5 7.571.7
PIKA-RV (high dose) 53.476.1 476.3732.4 50.475.4 79.1710.1 177.5710.1 19.073.7 143.5712.1 65.2721.6 8.471.8
Values are expressed as mean7standard deviation.
n, nn indicates signiﬁcant increase or decrease in value with p.
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different degree of myoﬁbrosis and inﬁltration of inﬂammatory
cells in a dose-dependent manner after the ﬁnal vaccination. All
animals returned to normal by the end of study period. No other
abnormality was seen in other organs examined.Discussion
Rabies remains one of the most important zoonotic disease in
many countries. According to WHO recommendation, in order to
protect people from developing rabies, those who were in category
III of exposure should receive both an effective rabies vaccine and
rabies immunoglobulin (RIG) (World Health Organization, 2013).
However, rabies immunoglobulins are in short supply throughout
the world and are virtually unaffordable in many developing
countries (Wilde et al., 2002). The previous results showed
immunization alone is not fully effective (Wang, 2010). Lin et al.
(1993) compared the efﬁcacy post-exposure of the aluminum
adjuvanted vaccine and the PICKCa adjuvanted vaccine. They
found aluminum adjuvanted vaccine did not enhance protection
while PIKA adjuvanted vaccine did. Similar results that PIKA
adjuvant vaccines are effective were also conﬁrmed in this study
(Figs. 3 and 4). In a study of Iran in 1954, anti-rabies serum and/or
vaccine were administered to 17 patients that had incurred severe
head wounds from one rabid wolf (World Health Organization,
2011). Among them, only one of 12 patients who received anti-
rabies serum plus vaccine died of rabies, while three of ﬁve
patients received only vaccine died of rabies. This phenomenon
showed vaccination alone is not effective to protect human from
rabies virus infection. The reasons are delayed generation of VNA
and weak cellular immunity, which were critical to prevent rabies
virus infection. So, it is important to develop a safer and efﬁcacious
vaccine against rabies.
As mentioned earlier, PIKA is a stabilized dsRNA that interacts
with TLR3. There have been several reports as to the humoral
immunity and cellular immunity induced by PIKA (Gai et al., 2011;
Lau et al., 2009, 2010; Shen et al., 2007; Tang et al., 2014; Zhang et
al., 2013). In this study, we ﬁrst assessed the immunogenicity of
PIKA adjuvanted rabies vaccine, including RVNA and cell mediated
immune response in vaccinated mice. We found that even though
the concentration of IPRV and PIKA was reduced to the standard
concentration of 1/10 (0.2 IU/mL and 0.1 mg/mL), the RVNA titer
was still signiﬁcantly higher than the IPRV alone (2 IU/mL). The
ELISPOT result also showed by formulating PIKA, antigen of 1/10
(0.2 IU) could signiﬁcantly improve IFN-γ secreting level than thestandard concentration of antigen (0.2 IU). Then we evaluated the
protective effect of PIKA-RV against rabies in Beagles and mice.
Compared with non-adjuvant vaccines, PIKA-RV enhanced the
protective activity of rabies vaccine injected after wild rabies strain
infection signiﬁcantly. In the study of efﬁcacy, PIKA-RV induced
higher RVNA titer, stronger cellular immunity, and showed better
protective effect, indicating the potential to develop next-
generation rabies vaccine.
Previous studies showed that PIKA could promote maturation of
dendritic cells (DCs) assessed by up-regulation of co-stimulatory
molecules CD80, CD86 and CD40, and the induction of cytokines
such as IL-12p70, IL-12p40 and IL-6 (Shen et al., 2007). DCs are
professional antigen-presenting cells located in the skin, mucosa and
lymphoid tissues. Their main function is to process antigens and
present them to T cells to promote immunity to foreign antigens. The
antigen signals from environment were recognized by PRR (pattern
recognition receptors), which are expressed on DCs, inducing differ-
ent immune responses toward the appropriate bias. TLRs are the
best-studied PRRs (Beutler, 2009). Because DCs are activated by PRRs,
then trigger the immune response cascade, TLRs are being interesting
targets for adjuvants. Indeed, there are several adjuvants based on
TLRs have been developed. AS04 (GSK) works by MPL-activation of
TLR4 and used as a vaccine for HBV and HPV. ISS (Dynavax) works by
activation of TLR9 and is used in vaccines against HBV and inﬂuenza.
IC31 (Intercell) works by activation of TLR9 and is used as a vaccine
against inﬂuenza and tuberculosis. PIKA is a mimicking viral dsRNA. It
is recognized by TLR3 and is well known to induce stable maturation
of DCs. This results in the induction of a Th1-type response, which
potentially remove virus-infected cells. Our results showed PIKA
vaccine protected mice against infection with wild rabies strains
effectively.
Studies have also shown that rabies virus attacks the nervous
tissue and appears to replicate almost exclusively in neuronal cells
(Warrell, 1997). Once introduced through the skin or mucous
membrane, the virus begins replicating in the striated muscles at
the wounded site. To block the rapid replication and migration of
rabies virus, vaccine should be administered to active the immune
system as soon as possible. In addition, as stated in the ICH S6:
“the route and frequency of administration should be as close as
possible to that proposed for clinical use”. Taking these in mind,
we proposed the accelerated regimen. Our results showed the
accelerated regimen did enhance the survival rate, which indicates
it is effective with the potential to develop a new regimen.
However, shorter dosing intervals and higher dose of vaccine
may increase the risk of vaccine-induced toxicity due to increased
inﬂammation and blood levels of vaccine. In view of developing
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safe, potent and affordable rabies vaccine, safety and pre-clinical
toxicity parameters have been evaluated in animal species.
Based on the acute dose toxicity study, all experimental ani-
mals did not show any clinical sign of toxicity for the entire test
period (14 days). Moreover, a repeated dose study was conducted
in mice. It has been found that after the ﬁnal vaccination, there
were different degree of myoﬁbrosis and inﬁltration of inﬂam-
matory cells in muscles around injection site of all treated groups.
However, by the end of study, all animals returned to normal,
which indicated that PIKA adjuvant and PIKA-RV did not show
obvious toxicity in local injection site.
For systemic reaction, studies of hematology, blood biochem-
istry, nonimmune organ and systemic pathological were con-
ducted. The results of nonimmune organ and systemic pathologi-
cal did not show obvious change. In the study of hematology, we
found there is the difference in HCT of high dose female group
compared with saline group on 2 days after the last treatment. In
our opinion, this difference lack biological signiﬁcance, since other
related values remain within normal range for the mice. HCT is the
volume percentage (%) of red blood cells in blood. RBC and HGB
can be quite helpful in evaluating a lower-than-normal HCT,
because they can help the clinician to determine whether patients
is suffering from anemia. However, the values of RBC and HGB of
high dose female vaccine group were similar with saline group,
and in normal range for the mice, which means the difference of
single indicator HCT is not a sign of toxicity.
Other differences in hematology indexes compared with saline
group were neutrophils and lymphocytes count. In our opinion,
the differences between males of high dose vaccine group and the
control group regards to neutrophils and lymphocytes count are
induced by the inﬂammatory reaction at the injection site, thus
provoking the mobilization of neutrophils to the affected area.
Neutrophils are the ﬁrst immune cells to arrive at a site of
inﬂammation (Wang and Arase, 2014). Lymphocytes are the cells
that determine the speciﬁcity of the immune response to infec-
tious microorganisms and other foreign substances. Granulocytes
may also help to initiate adaptive immune responses, as they play
a key role in initiating adaptive immunity by releasing important
cytokines that attract monocytes and dendritic cells and inﬂuence
whether macrophages differentiate to a predominantly pro- or
anti-inﬂammatory state (Mancebo et al., 2012). So the increased
number of neutrophils and the decreased number of lymphocytes
indicated the development of inﬂammation. By the end of study,
these changes disappeared and the counts returned to normal
range. Although the statistical analysis failed to show these dif-
ferences in females, the observation of data in Table 1b illustrates
clearly that this gender showed the same behavior.
ALT and AST levels are considered to be two of the most
important parameters to detect liver injury (Goorden et al., 2013),
and ALT is more speciﬁc for liver toxicity and is more commonly
elevated rather than AST. In the study of blood biochemistry, male
PIKA-treated group showed signiﬁcantly higher level of AST than
saline group 2 days after the last administration. To determine
whether liver disease is present, AST levels are usually compared
with results of other tests, such as ALP, total protein, and bilirubin.
However, in this study, there was no obvious change in other
related values of PIKA-treated group, especially ALT. Therefore, the
change of AST is not an effective indication of toxicity. Further-
more, the level of AST in male PIKA-treated group returned to
normal at the end of the study.
ALP is a group of enzymes primarily found in liver and bone
(Song et al., 2011; Suzuki, 1986). They act by splitting off phos-
phorus (an acidic mineral) creating an alkaline pH. The primary
importance of measuring alkaline phosphatase is to check the
possibility of bone disease or liver disease. Because acid–alkaline isinﬂuenced by many other organs/glands including adrenals,
uterus, prostate, and intestine, the implications of serum alkaline
phosphatase levels must consider more than just bone and liver
function. Although the serum levels of ALP in all female PIKA
treated groups showed signiﬁcant decrease compared to Saline
group, none of other biomarkers showed alterations and none of
the animals of treated groups showed organ lesions. Besides, the
difference of ALP had also disappeared by the end of study. Thus,
the temporary change of ALP level was not a sign of toxicity.
In the study of immune toxicity, immune organ and histopathol-
ogy were observed. There was a signiﬁcant increase of spleen weight
in PIKA-treated and PIKA vaccine-treated groups when compared to
saline group, in both gender, 2 days after last immunization. In
addition, inguinal lymph nodes around the injection site and spleen
showed different degree of hyperplasia. Considering increased neu-
trophil count and reduced lymphocytes, which was observed in this
study, the increased weight in the spleen and the hyperplasia of
lymph nodes were associated to stimulation of the immune system;
this could be considered as indicators of the immunological action of
the adjuvants. While hyperplasia of the spleen and lymph nodes
returned to normal by the end of study period, which means PIKA
adjuvant and PIKA-RV showed no toxicity in immune organs. In
another related study, the immune toxicity of PIKA-RV in monkeys
including antinuclear antibody test, CD4/CD8 level and histological
examination of immune system (unpublished results) showed that
PIKA adjuvant and PIKA-RV do not cause immune toxicity.Conclusions
In summary, PIKA-RV enhance both humoral and cellular
immunity. Administered with an accelerated regimen, the PIKA-RV
protected 80% of the mice after viral challenge. According to the
results of toxicity study, it is suggested that the PIKA and PIKA-RV
are well tolerated in mice and can be considered safe. The pre-
sented preclinical results support the start of the ﬁrst clinical
studies with PIKA rabies vaccine. This would allow to further
explore its safety in humans and also be a broad potential coverage
against wild-type rabies strains.Materials and methods
Animals
Speciﬁc pathogen-free (SPF) female BALB/c mice were pur-
chased from the Beijing Laboratory Animal Center for evaluation of
the immune response of PIKA-RV. Beagles were purchased from
Beijing Rixin Technology Co., Ltd. for post-exposure efﬁcacy test.
Golden hamsters were purchased from Changchun Institute of
Biological Products Co., Ltd. for post-exposure efﬁcacy test. For
acute and repeated dose toxicity studies, Kunming mice were
purchased from Vital River Laboratories. Mice and hamsters were
kept under SPF requirement. Beagles were kept under clean
environment. All animals were treated according to the regula-
tions of Chinese law and the local Ethical Committee.Viruses
Wild virus strain BD06 in viral challenge test was isolated from
infected dog and maintained by Veterinary Institute, Academy of
Military Medical Sciences, China.
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PIKA, inactivated puriﬁed rabies virus (IPRV) and PIKA-RV were
produced by Liaoning Yisheng Biopharma Co. Ltd. The standard
PIKA-RV containing 2.0 IU IPRV and 1.0 mg PIKA adjuvant was
freeze-dried and reconstitute with 1.0 mL of water for injection
(WFI) before use. The vaccine control used in animal (Golden
Hamster) regimen studies was manufactured by Novartis, which
contains inactivated rabies virus without adjuvant.
Evaluation of the immune response of PIKA-RV
Five groups of six mice (6–8 weeks old, weighted 18–22 g)
were immunized by intramuscular (i.m.) injection with different
concentration (0.2 IU IPRVþ100 μg PIKA, 0.02 IU IPRVþ10 μg
PIKA, 0.002 IU IPRVþ1 μg PIKA, or 0.2 IU IPRV) in a volume of
100 μl., or a PBS control. The preparations were injected into mice
on days 0 and 7.
Serum samples were collected at day 21 after the ﬁrst immuni-
zation and the virus neutralizing antibody (RVNA) titers were eval-
uated using FAVN test (ﬂuorescent antibody virus neutralization test)
as described previously (Cliquet et al., 1998), which is a standardized
test recommended by World Health Organization (WHO).
Mice were sacriﬁced at day 21 after the ﬁrst immunization, and
splenocytes were prepared. The frequency of IFN-γ secreting cells
was analyzed using commercial mouse IFN-γ ELISPOT kits (BD,
America) following the manufacturer's instructions. Spots were
counted using an automated ELISPOT reader (ChampSpot II, Sage
Creation, China). The mean spot number7SD of triplicate wells for
each stimulation antigen or control was calculated.
Post-exposure efﬁcacy test in Beagles
Three groups of Beagles, 10 Beagles in each group, were
infected i.m. with 160,000 LD50 BD06 rabies virus and then
immunized with different preparations post infection. Animals
were administered with (1) PBS, (2) vaccine control or (3) PIKA-
RV. For PBS and vaccine control groups, animals were injected on
days 0, 3, 7, 14 and 21. For PIKA-RV group, animals were received
double dose injection on day 0 and 3 post exposure and one dose
injection on day 7, 10 and 14 post exposure. Infected and treated
animals were observed for 45 days post-challenged for the
development of rabies-speciﬁc symptoms or death conﬁrmed by
direct ﬂuorescent antibody test (DFA) and percentage survival rate
was calculated.
Post-exposure efﬁcacy test in golden hamsters
Female golden hamsters (7–8 weeks old, weighted 100–150 g)
were randomized into 5 groups with different immunization
schedules. Animals were previously i.m. infected with 0.1 mL of 50
LD50 wild rabies viruses (BD06 strain) at the hind legs. Animals
were treated with (1) saline solution by standard regimen,
(2) vaccine control by standard regimen, (3) human rabies
immunoglobulin (HRIG, 0.75IU administered at each site of right
and left hind leg 2 h post exposure), (4) PIKA-RV by standard
regimen, or (5) PIKA-RV by accelerated regimen respectively post
infection. For standard regimen, animals were injected on day 0, 3,
7, 14, and 28 respectively. For accelerating regimen, animals were
received double dose injection on day 0 and 2 post exposure and
another injection on day 7 post exposure. All animals were
observed for 45 days post-challenged for the development of
rabies-speciﬁc symptoms or death conﬁrmed by DFA test and
percentage survival rate was calculated.Acute toxicity test
Kunming mice weighted 17–20 g were divided into 4 groups with
20 mice in each group (10 male and 10 female) for single dose
immunization. Mice were administered with 0.2 mL of (1) PBS
negative control, (2) PIKA (1000 μg/mL PIKA), (3) PIKA-RV (1 IU/mL
IPRVþ500 μg/mL PIKA), or (4) PIKA-RV (2 IU IPRVþ1000 μg/mL
PIKA) respectively. They were observed closely for 4 h, immediate
toxic reactions, death and abnormal clinical symptom were recorded.
Mice were observed for another 14 days for body weight, food intake,
behavior changes, death and abnormal clinical symptoms before
sacriﬁced for macrophathology examination of organs.
Repeated dose toxicity test
Kunming mice weighted 16–22 g were divided into 4 groups
with 40 mice in each group (20 male and 20 female) for repeated
dose immunization. Mice were administered i.m. with (1) saline
control, (2) PIKA adjuvant (1000 μg/mL PIKA), (3) low dose of
PIKA-RV (1 IU/mL IPRVþ500 μg/mL PIKA), or (4) high dose of
PIKA-RV (2 IU IPRVþ1000 μg/mL PIKA) respectively. The vaccina-
tion schedule evolved double dose (0.2 mL) administration at each
side of the forelimbs on day 0 and day 2, and single dose (0.1 mL)
administration in one of the forelimbs on days 7, 28 and 42.
The injection site and systemic clinical symptoms were
observed 30 min before and after injection, once per hour up to
4 h and twice every day post-injection. Food intake and body
weight were measured weekly throughout the study. Average food
intake was calculated after each 7-day period to avoid daily ﬂuc-
tuations. Blood samples were obtained after the last vaccination
dose on day 44 and during animal recovering period by day 56 for
hematology and biochemistry tests.
Hematology parameters
The hematology parameters analyzed in the test include: white
blood cell count (WBC), red blood cell count (RBC), hemoglobin
(HGB), hematocrit (HCT), mean corpuscular volume (MCV), mean
corpuscular hemoglobin (MCH), mean corpuscular hemoglobin
concentration (MCHC), platelet (PLT), red cell distribution width
(RDW), thrombocytocrit (PCT), mean platelet volume (MPV), pla-
telet distribution width (PDW), reticulocyte count (Ret), lympho-
cyte (LY), monocyte (MO), and neutrophile granulocyte (GR). The
analytical reagents were purchased from Shanghai Donghu Bio-
medicine Pte Ltd. (China).
Biochemistry parameters
The biochemistry parameters analyzed in the test include: Alanine
Transaminase (ALT), Aspartate Transaminase (AST), total protein (TP),
albumin, total bilirubin, urea, creatinine, glucose (Glu), creatinine
kinase (CK), Alkaline phosphatase (ALP), cholesterol (CHO), triglycer-
ide (TG), sodium (Naþ), serum phosphate (Kþ), serum chloride (Cl).
Various test kits purchased from BIOSINO Bio-technology and Science
Inc. were used for analysis. The analytical reagents were purchased
from Randox Laboratories (China).
Histology examinations
After the ﬁnal vaccination and by the end of study period, 10
male and 10 female animals were randomly picked from each
study, and they were sacriﬁced for histological examination. Sec-
tions of the following preserved tissues were processed by stan-
dard histological procedures: adrenals, aorta, axillary lymph node,
bone marrow, brain, cecum, colon, duodenum, epididymides,
esophagus, eyes, gross lesions, heart, ileum, inguinal lymph nodes,
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nodes, optic nerve, ovaries, pancreas, parathyroid glands, pituitary,
prostate, rectum, salivary glands, seminal vesicles, spinal cord
(cervical, thoracic and lumbar), spleen, stomach, testes, thymus,
thyroid gland, trachea, urinary bladder, uterus vagina, seminal
vesicle, sciatic nerve and skeletal muscle of the injection site.
The following organs were weighed: brain, thymus, lungs,
heart, spleen, liver, adrenals, kidneys, testes (males), epididymides
(males), uterus (females) and ovaries (females). The ratios of organ
weight to terminal body weight were calculated.
Statistical analysis
The data on variations of antibodies and IFN-γ secreting cells were
conducted using GraphPad Prism5 software (San Diego, CA, USA).
Results have been expressed as mean7SEM values. Differences
between the treatment groups were evaluated by one-way ANOVA
with signiﬁcance determined by Tukey-adjusted t-tests. The data on
variations of body weights, feed consumption, hematology, biochem-
istry and organ weight were analyzed between control groups and
study groups by ANOVA using SPSS according to gender difference.Acknowledgments
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